전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved381 programs
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 25Status Recruiting
ADCStandard DatabasestaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
CGTStandard DatabasestaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
AntibodyLimited DatastaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 16Status Active
CGTLimited DatastaleBeam Therapeutics Inc.Phase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Recruiting
CGTLimited DatastaleShanghai Mingju Biotechnology C…Phase 1

JWCAR029 (JWCAR029)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 14Status Active
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 2

Anti-CD22-CAR-transduced T cells (Anti-CD22-CAR-transduced T cells)

Leukemia; Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 13Status Active
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

Anti-CD30 CAR T cells (Anti-CD30 CAR T cells)

Adult T-Cell Lymphoma/Leukaemia; Anaplastic Large Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 13Status Active
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 13Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 13Status Active
ADCStandard DatabasestaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 12Status Recruiting
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19A (ThisCART19A)

Non-Hodgkin's Lymphoma · Allogeneic, CAR-T, Protein Sequestration

#AllogeneicCAR-TProteinSequestrat#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 12Status Recruiting
CGTLimited DatastaleTaiho Oncology, Inc.Phase 2

ASTX660 (ASTX660)

Solid Tumors; Lymphoma · Solid Tumors

#SolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 11Status Recruiting
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
CGTLimited DatastaleNovartisPhase 1

huCART19 (huCART19)

Acute Lymphocytic Leukemia; Diffuse Large Cell Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 10Status Active

4 / 20 pages

← PreviousNext →